Stay updated on Johnson & Johnson Press Releases

Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Johnson & Johnson Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    Expanded clinical/regulatory spotlight with many new approvals, trial results, and conference appearances; removed an older foundation investment note and several earlier items.
    Difference
    100%
    Check dated 2025-10-11T09:49:50.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Difference
    24%
    Check dated 2025-10-04T02:51:07.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Summary: The page now adds new items on seltorexant’s potential benefit in depression with insomnia and a $5M expansion by the J&J Foundation for community health workers, while removing recent NSCLC trial news about rybrevant lazertinib. The focus shifts toward mood disorder pharmacology and health workforce investment at the expense of oncology first-line therapy news.
    Difference
    34%
    Check dated 2025-09-27T02:06:50.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Significant new content about drug approvals, clinical trial results, and product launches has been added, increasing the page’s core informational value. Some older items (2,188 results) appear removed, but the key updates are materially important.
    Difference
    100%
    Check dated 2025-09-19T22:46:38.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    New high-impact drug approvals and trial updates plus leadership/news events have been added, while older manufacturing/investment notices and prior event mentions were removed.
    Difference
    100%
    Check dated 2025-09-12T17:13:14.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated with significant new clinical study results and product approvals, including the survival benefits of RYBREVANT® and LAZCLUZE® in treating EGFR-mutated NSCLC, as well as new data on maternal-fetal immunology and the VARIPULSE™ Platform. Additionally, the page reflects a slight increase in search results from 2,178 to 2,183.
    Difference
    100%
    Check dated 2025-09-05T13:50:39.000Z thumbnail image

Stay in the know with updates to Johnson & Johnson Press Releases

Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.